Dimerix (ASX:DXB) is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix’ lead clinical asset, QYTOVRA®, is in Phase 3 trials as a treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease with first interim analysis expected in March 2024. In addition, DMX-700 is under development for Chronic Obstructive Pulmonary Disease (COPD). Both QYTOVRA® and DMX-700 drug candidates were identified using Dimerix’ proprietary Receptor-HIT assay, which can be leveraged to identify new opportunities, strengthening the company’s development pipeline and diversifying development risk.